Dublin, Jan. 02, 2019 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing Market by Type, Disease, Application, End User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The viral vector manufacturing market is expected to reach USD 815.8 million by 2023 from an estimated USD 327.8 million in 2018, at a CAGR of 20.0%.

The growth of this market is expected to be driven by rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. On the other hand, the high cost of gene therapies and short shelf-life of viral vectors are likely to restrain the growth of this market to a certain extent.

The genetic disorders segment is expected to grow at the highest rate during the forecast period

By disease, the viral vector manufacturing market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. During the forecast period, the genetic disorders segment is expected to grow at the highest CAGR owing to the accelerated research activities on various genetic disorders such as hemophilia A and B, sickle cell anemia, and Huntington's disease.

The pharmaceutical and biopharmaceutical companies to hold the largest share of the market

Based on end user, the global viral vector manufacturing market is segmented into pharmaceutical and biopharmaceutical companies and research institutes. The pharmaceutical and biopharmaceutical companies segment is expected to hold the largest share of the market in 2018. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the pharmaceutical and biopharmaceutical companies segment during the forecast period.

North America is expected to dominate the viral vector manufacturing market in 2018

In 2018, North America is expected to account for the largest share of 64.8% of the global viral vector manufacturing market. Factors such as a large number of regenerative medicine companies (including gene and cell therapy companies), increasing research activities, rising prevalence of target diseases, and availability of funding are supporting the growth of the viral vector manufacturing market in North America.

The major players in the global viral vector manufacturing market are Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US).

Key Topics Covered:

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Currency
1.4 Stakeholders

2 Research Methodology
2.1 Primary Data
2.2 Secondary Data
2.3 Market Size Estimation
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Market Overview

5 Market Overview
5.1 Introduction
5.2 Evolution
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
5.3.1.2 Availability of Funding for the Development of Gene Therapy
5.3.1.3 Effectiveness of Viral Vectors
5.3.1.4 Ongoing Research Into Viral Vector-Based Gene and Cell Therapies
5.3.2 Restraints
5.3.2.1 High Costs Associated With Gene Therapy
5.3.2.2 Short Shelf-Life of Viral Vectors
5.3.3 Challenges
5.3.3.1 Risk of Mutagenesis and Other Unwanted Outcomes

6 Viral Vector Manufacturing Market, By Type
6.1 Introduction
6.2 Retroviral Vectors
6.2.1 Lentiviral Vectors
6.2.2 Gamma-Retroviral Vectors
6.3 Adenoviral Vectors
6.4 Adeno-Associated Viral Vectors
6.5 Other Viral Vectors

7 Viral Vector Manufacturing Market, By Disease
7.1 Introduction
7.2 Cancer
7.3 Genetic Disorders
7.4 Infectious Diseases
7.5 Other Diseases

8 Viral Vector Manufacturing Market, By Application
8.1 Introduction
8.2 Gene Therapy
8.3 Vaccinology

9 Viral Vector Manufacturing Market, By End User
9.1 Introduction
9.2 Pharmaceutical and Biopharmaceutical Companies
9.3 Research Institutes

10 Viral Vector Manufacturing Market, By Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 Rest of the World

11 Competitive Landscape
11.1 Overview
11.1.1 Product Approval
11.1.2 Collaborations, Partnerships, and Agreements
11.1.3 Acquisitions and Mergers
11.1.4 Expansions

12 Company Profiles
12.1 Lonza
12.2 Merck KGaA
12.3 Oxford Biomedica
12.4 Cobra Biologics
12.5 Novasep
12.6 Spark Therapeutics
12.7 Kaneka Eurogentec
12.8 Finvector Vision Therapies
12.9 Brammer Bio
12.10 Cell and Gene Therapy Catapult (CGT Catapult)
12.11 Fujifilm Holdings Corporation
12.12 Uniqure
12.13 Regenxbio
12.14 Massbiologics

For more information about this report visit https://www.researchandmarkets.com/research/5z65ss/global_800_mn?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics

Ads